ArticlePakistan journal of medical sciences2026
The value of antinuclear antibody spectrum in diagnosis and disease activity assessment in early atypical systemic lupus erythematosus.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the value of antinuclear antibody spectrum(ANAs) in diagnosis and disease activity assessment in early atypical systemic lupus erythematosus(SLE). Methodology: A retrospective analysis was conducted on the clinical data of 77 patients with early atypical SLE(the SLE group) from January 2023 to June 2025 in Affiliated Hospital of Hebei University, while the clinical data from 40 patients with other rheumatic diseases during the same period were selected as the non-SLE group. All 117 patients underwent serum ANAs detection using immunoblotting to compare the diagnostic value of the ANAs and combination detection for SLE. The 77 SLE patients were divided into the active(n= 43) and non-active disease(n= 34) groups following the SLE Disease Activity Index(SLEDAI), with multivariate logistic regression analysis adopted to identify risk factors affecting disease activity in SLE patients. Results: The positivity rates of ANA, anti-dsDNA, anti-Sm, anti-AunA, anti-SSA, anti-SSB, and anti-rRNP in the SLE group were significantly higher than those in the non-SLE group( Conclusion: ANAs is of significant value in diagnosis and disease activity assessment in early atypical SLE. More accurate diagnostic and clinical assessment references could be provided through the detection of various ANAs antibodies and their combinations, along with multivariate analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.